Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
- Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies
- Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome
- New data evaluating investigational medicines in Genmab’s early portfolio of cancer immunotherapies will also be presented
-
Genmab to host 2022 R&D Update and ASH Data Review meetingDecember 12
Additionally, abstracts evaluating two investigational medicines in Genmab’s early pipeline have been accepted for presentation, including the first-in-human data from the phase 1/2 trial evaluating GEN3014 (HexaBody®-CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM). In addition, preclinical data from a novel drug candidate GEN3017 (DuoBody®-CD3xCD30) will also be presented.
All abstracts accepted for presentation have been published on the ASH website.
Epcoritamab is being co-developed by
“As part of our commitment to the blood cancer community, we continue to advance our research and innovative technologies in an effort to develop differentiated therapies with the goal of transforming the future of treatment for patients,” said Dr.
2022 R&D Update and ASH Data Review
On
Abstracts accepted at ASH:
Epcoritamab (DuoBody®-CD3xCD20)
Abstract Number |
Abstract Title |
Type of Presentation |
Date/Time of Presentation |
348 |
Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1). Kater et. al. |
Oral |
|
443 |
Subcutaneous Epcoritamab + R-DHAX/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results. Abrisqueta et. al. |
Oral |
|
609 |
Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update. Falchi et. al. |
Oral |
|
611 |
Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial. Falchi et. al. |
Oral |
|
4251 |
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Phillips et. al. |
Poster |
|
3580 |
Improvements in Lymphoma Symptoms and Health-related Quality of Life in Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Epcoritamab. Phillips et. al. |
Poster |
|
4912 |
Indirect Comparison of the Efficacy of Subcutaneous Epcoritamab Dose Expansion (EPCORE NHL-1 Trial) in Patients With Relapsed or Refractory Large B-cell Lymphoma. Salles et. al. |
Poster |
|
2874 |
Deep peripheral T cell subset immune-profiling in relapse/refractory non-Hodgkins lymphoma (NHL): Evaluation of baseline samples from the Epcoritamab 3013-01 trial. Blum et. al. |
Poster |
|
2859 |
Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory versus Newly Diagnosed Patients with Single Slides. Jabado et. al. |
Poster |
|
1663 |
Phase 1b Trial of Subcutaneous Epcoritamab Among Pediatric Patients With Relapsed or Refractory Aggressive Mature B-Cell Neoplasms. |
Poster |
|
4182 |
Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-cell non-Hodgkin’s Lymphoma (NHL). Epling-Burnette et. al. |
Poster |
|
4206 |
Phase 3 Trial of Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide (R2) vs R2 Without Epcoritamab Among Patients With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1). Falchi et. al. |
Poster |
|
4271 |
Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients With Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma. Sharman et. al. |
Poster |
|
5524 |
Assessing Safety, Tolerability, and Efficacy of Subcutaneous Epcoritamab in Novel Combinations with Anti-Neoplastic Agents in Patients with Non-Hodgkin Lymphoma in a Phase 1b/2, Open-Label Study. Sehn et. al. |
Publication |
NA |
GEN3014 (HexaBody®-CD38)
Abstract Number |
Abstract Title |
Type of Presentation |
Date/Time of Presentation |
3254 |
Preliminary Dose-Escalation Results From a First-in-Human Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) With Relapsed or Refractory (R/R) Multiple Myeloma (MM). Spencer et. al. |
Poster |
|
GEN3017 (DuoBody®-CD3xCD30)
Abstract Number |
Abstract Title |
Type of Presentation |
Date/Time of Presentation |
1366 |
DuoBody®-CD3xCD30 shows potent preclinical anti-tumor activity in vitro in CD30+ hematologic malignancies. Oostindie et. al. |
Poster |
|
Real-World Evidence
Abstract Number |
Abstract Title |
Type of Presentation |
Date/Time of Presentation |
2978 |
Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Standard of Care: a COTA Database Analysis. Ip et. al. |
Poster |
|
2296 |
Treatment Patterns and Outcomes in Patients With Follicular Lymphoma Receiving at Least 3 Lines of Therapy: a Real-World Evaluation in |
Poster |
|
2215 |
Health Care Resource Utilization and Costs of CAR T Therapy in Patients With Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis. Davies et. al. |
Poster |
|
About Epcoritamab
Epcoritamab is an investigational IgG1-bispecific antibody created using
About
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the
_______________________
i Engelberts et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625
ii Rafiq, Butchar, Cheney, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and
iii Singh,
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005411/en/
T: +1 609 613 0504; E: dafr@genmab.com
For Investor Relations:
T: +45 3377 9558; E: acn@genmab.com
Source: